EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA, May 12-16, 2017

EDAP to Showcase Ablatherm Fusion and Sonolith i-move at AUA Booth #130

LYON, France, May 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it will demonstrate capabilities of its range of products including Ablatherm® Robotic HIFU and Sonolith i-move lithotripter on booth #130 at the American Urology Association ("AUA") Annual Meeting, to be held May 12-16, 2017 in Boston, MA. Live demonstrations will be conducted by experts from world-class US and International academic centers throughout the meeting. Key opinion leaders and experts will be participating in sessions where HIFU technology will be discussed and clinical results of HIFU for ablation of the prostate presented. 

During AUA, EDAP will also present the world premiere of the Ablatherm® Fusion, the next generation of the Ablatherm Robotic HIFU device integrating EDAP's proprietary elastic fusion algorithm. This new device will allow urologists to import pre-treatment diagnostic information such as MRI images and 3D biopsy maps and merge them with the live ultrasound image during the procedure. This new, innovative device creates a distinct advantage positioning Ablatherm Robotic HIFU as the ideal device for prostate tissue ablation by increasing and improving its capacity to provide optimal patient treatment and to preserve patient quality of life.

Marc Oczachowski, EDAP's Chief Executive Officer, commented: "We are thrilled to introduce this innovative product that enables novel therapeutic strategies for the ablation of prostate tissues. Additionally, this expansion to our range of HIFU offerings creates a new option for hospitals and urologists, allowing EDAP to serve a broader range of customers at a variety of price points."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is not yet available in the U.S. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA cleared. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and  http://www.hifu-planet.com.

Forward Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Investor Contact

CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital

Company Contact

Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

News Provided by Acquire Media